Cardiology
Tenax Therapeutics enrolls first patient in phase 3 trial for pulmonary hypertension treatment
February 8, 2024Research and Development Cardiology, Tenax Therapeutics, clinical trial, pulmonary hypertension
Tenax Therapeutics has announced that it has enrolled the first patient in its phase 3 LEVEL study, which aims to …
AstraZeneca shares results from phase 3 trial of acoramidis in adults with ATTR-CM
February 2, 2024Research and Development ATTR-CM, AstraZeneca, Cardiology, acoramidis, clinical trial
AstraZeneca has announced positive high-level results from the phase 3 trial of acoramidis in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) …
Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment
November 27, 2023Medical Communications COPD, Cardiology, Dupixent, Sanofi, clinical trial
Sanofi and Regeneron have announced results from the second investigational phase 3 NOTUS trial for Dupixent as a treatment for …
Acesion Pharma raises €45m series B funding
September 26, 2023Business Services Acesion Pharma, Cardiology, atrial fibrillation, series B financing
Acesion Pharma has announced that it has closed an oversubscribed €45m series B financing round. This financing was co-led by …
Novo Nordisk acquires Embark Biotech and its lead metabolic programme
August 31, 2023Business Services Cardiology, Novo Nordisk, Obesity, acquisition, metabolics, obesity
Novo Nordisk has officially acquired the biopharmaceutical company Embark Biotech, along with its lead asset metabolic programme. The teams will …
AstraZeneca’s Forxiga approved in China for chronic heart failure treatment
August 18, 2023Medical Communications AstraZeneca, Cardiology, China, cardiovascular, heart failure
AstraZeneca has announced that Forxiga (dapagliflozin) has been approved in China to reduce the risk of cardiovascular death, hospitalisation for …
Novo Nordisk’s Wegovy reduces risk of cardiovascular events
August 9, 2023Research and Development Cardiology, Novo Nordisk, Wegovy, cardiovascular, cvd, semaglutide
Novo Nordisk has shared results from the SELECT cardiovascular outcomes trial, which show that a once weekly subcutaneous dose of …
Amarin’s Vazkepa accepted by SMC for patients with cardiovascular disease
August 8, 2023Research and Development Cardiology, Vazkepa, cardiovascular disease, pharmaceutical
On 7 August 2023, the Scottish Medicines Consortium (SMC) announced that they had accepted Amarin’s treatment for people with cardiovascular …
Evox Therapeutics enters agreement for next generation gene therapy for heart disease
August 4, 2023Research and Development Cardiology, Evox Therapeutics, Icahn Mount Sinai, cvd, gene therapy
Evox Therapeutics has announced a research collaboration and option agreement with the Icahn School of Medicine at Mount Sinai (Icahn …
Ionis and Novartis partner for CVD treatment programme
August 4, 2023Business Services Cardiology, Ionis Pharmaceuticals, License Agreement, Novartis, cvd
Ionis Pharmaceuticals has announced that it has entered into a new collaboration and license agreement with Novartis, aiming to discover, …
American Heart Association awards $2.1m to research link between migraine, strokes and CVD
July 27, 2023Research and Development American Heart Association, Cardiology, cvd, migraine, stroke
The American Heart Association has announced that it will fund seven new scientific research studies to learn more about the …
Amarin gains positive opinion from Spanish Drug Pricing Committee for national reimbursement of Vazkepa in Spain
July 26, 2023Sales and Marketing Amarin, Cardiology, Spanish Drug Pricing Committee, Vazkepa, cardiovascular
Amarin has announced that the Spanish Drug Pricing Committee has recommended the national reimbursement of Vazkepa (icosapent ethyl) in Spain …
Alnylam and Roche partner for RNAi therapeutic for treatment of hypertension
July 24, 2023Research and Development Alnylam, Cardiology, Roche, hypertension, rnai, zilebesiran
Alnylam Pharmaceuticals has announced that it has entered a strategic agreement with Roche for the development and commercialisation of zilebesiran, …
Renibus Therapeutics announces $47m financing for phase 3 trial
July 19, 2023Business Services Cardiology, Financing, Renibus Therapeutics, clinical trial
Clinical stage biopharmaceutical company Renibus Therapeutics has announced that it has raised $47m from the initial closing of its Series …
Eli Lilly to acquire Versanis Bio for $1.9bn
July 17, 2023Sales and Marketing Cardiology, Eli Lilly, Versanis Bio, acquisition, cardiometabolic diseases
Eli Lilly and Versanis Bio have announced a definitive agreement for Lilly to acquire Versanis, a private clinical-stage biopharmaceutical company …
Latest content
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes
Ofichem acquires US drug substance CDMO Kinentia
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ
